HIV/AIDS vaccine development: Challenges, progress and future directions

Reviews in Medical Virology

Volumn 6, Issue 3, 1996, Pages 123-140

  Johnston, Margaret I ^a,b  

^a ROCKEFELLER FOUNDATION   (United States)

^b 1400 I Street NW ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; SYNTHETIC PEPTIDE; VIRUS GLYCOPROTEIN; VIRUS VECTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNITY; INFECTION CONTROL; REVIEW; VACCINATION; VIRUS ENVELOPE;

EID: 0029816233     PISSN: 10529276     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1654(199609)6:3<123::AID-RMV170>3.0.CO;2-Y     Document Type: Review

References (184)

1. Gallo, R. C., Sarin, P. S., Gelmann, E. P. et al. (1983). Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS) T. Science 220, 865-867.
2. Bryson, Y. J., Pang, S., Wei, L. S., Dickover, R., Diagne, A. and Chen, I. S. Y. (1995). Clearance of HIV infection in a perinatally infected infant. N Engl. J. Med. 332, 833-838.
3. Rowland-Jones, S., Sutton, J., Ariyoshi, K. et al. (1995). HIV-specific cytotoxic T-cell in HIV-exposed but uninfected Gambian women. Nature Med. 1, 59-64.
4. Miller, C.J., Marthas, M., Torten, J. et al. (1994). Intravaginal inoculation of rhesus macaques with cell-free simian immunodeficiency virus results in persistent or transient viremia. Eng. J. Virol. 68, 6391-6400.
5. Mellors, J. W., Kingsley, L. A., Rinaldo, C. R. et al. (1995). Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann. Intern. Med. 122, 573-579.
6. Pantaleo, G., Menzo, S., Vaccarezza, M. et al. (1995). Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N. Engl. J. Med. 332, 209-216.
7. Cao, Y., Qin, L., Zhang, L., Safrit, J. and Ho, D. D. (1995). Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N. Engl. J. Med. 4, 201-208.
8. Pantaleo, G., Graziosi, C., Demarest, J. F. et al. (1993). HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease [see comments]. J. Virol. 362, 355-358.
9. Heath, S. L., Tew, J. G., Tew, J. G., Szaka, A. K. and Burton, G. F. (1995). Follicular dentritic cells and human immunodeficiency virus infectivity. Nature 377, 740-744.
10. Arthur, L. O., Bess, J. W., Jr., Sowder, R. C. (1992). Cellular proteins bound to immunodeficiency viruses: implications for pathogenesis and vaccines. Science 258, 1935-1938.
11. Gomez, M. P. and Hildreth, J. E. K. (1995). Antibody to adhesion molecule LFA-1 enhances AIDS plasma neutralization of HIV-1. J. Virol. 69, 4628-4632.
12. Berman, P. W. and Nakamura, G. R. (1994). Adhesion mediated by intercellular adhesion molecule 1 attenuates the potency of antibodies that block HIV-1 gp160-dependent syncytium formation. AIDS Res, Hum. Retrovir. 10, 585-593.
13. Fultz, P. N. (1989). Nonhuman primates and the acquired immunodeficiency syndrome: a union of necessity. J. Med. Primatol. 18, 73-83.
14. Schultz, A. M. and Hu, S. L. (1993). Primate models for HIV vaccines. Aids 7 (Suppl.) S161-S170.
15. Novembre, F. J., Saucier, M. M., Anderson, D. C. et al. (1996). AIDS in a chimpanzee infected with HIV-1, 3rd Conference on Retroviruses and Opportunistic Infections 92 Abstract, Infectious Disease Society of America, Alexandria, VA.
16. Desrosiers, R. C. (1996). Non-human primate models for AIDS vaccines. Aids 9 (Suppl. A), S137-S141.
17. Luciw, P. A., Shaw, K. E., Unger, R. E. et al. (1992). Genetic and biological comparisons of pathogenic and nonpathogenic molecular clones of simian immunodeficiency virus (SIVmac). AIDS Res. Hum. Retrovir. 8, 395-402.
18. Letvin, N. L. (1992). Nonhuman primate models for HIV vaccine development. Immunodefic. Rev. 3, 247-260.
19. Hirsch, V. M., Dapolito, G. A., Goldstein, S. et al. (1993). A distinct African lentivirus from Sykes' monkeys. J. Virol. 67, 1517-1528.
20. Allan, J. S., Short, M., Taylor, M. E. et al. (1991). Species-specific diversity among simian immunodeficiency viruses from African green monkeys. J. Virol. 65, 2816-2828.
21. Johnson, P. R., Goldstein, S., London, W. T., Fomsgaard, A. and Hirsch, V. M. (1990). Molecular clones of SIVsm and SIVagm: experimental infection of macaques and African green monkeys. J. Med. Primatol. 19, 279-286.
22. Talbott, R. L., Sparger, E. E., Lovelace, K. M. et al. (1989). Nucleotide sequence and genomic organization of feline immunodeficiency virus. Proc. Natl Acad. Sci. USA 86, 5743-5747.
23. Li, J., Lord, C. I., Haseltine, W., Letvin, N. L. and Sodroski, J. (1992). Infection of cynomolgus monkeys with a chimeric HIV-1/SIVmac virus that expresses the HIV-1 envelope glycoproteins. J. AIDS 5, 639-646.
24. Li, J. T., Halloran, M., Lord, C. I. et al. (1995). Persistent infection of macaques with simian-human immunodeficiency viruses. J. Virol. 69, 7061-7071.
25. Myers, G. (1994). Tenth anniversary perspectives on AIDS. HIV: between past and future. AIDS Res. Hum. Retrovir. 10, 1317-1324.
26. Vanden Haesevelde, M., Decourt, J. L., De Leys, R. J. et al. (1994). Genomic cloning and complete sequence analysis of a highly divergent African human immunodeficiency virus isolate. Engl. J. Virol. 68, 1586-1596.
27. Louwagie, J., Jassens, W., Mascola, J. et al. (1995). Genetic diversity of the envelope glycoprotein from human immunodeficiency virus type 1 isolates of African origin. J. Virol. 69, 263-271.
28. Robertson, D. L., Hahn, B. H. and Sharp, P. M. (1995). Recombination in AIDS viruses. J. Mol. Evolut. 40, 249-259.
29. Kostrikis, L., Cao, Y., Ngai, H., Moore, J. P. and Ho, D. D. (1996). Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I: Lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement. J. Virol. 70, 445-458.
30. Moore, J. P., Cao, Y., Leu, J., Qin, L., Korber, B. and Ho, D. H. (1996). Inter- and intraclade neutralization of human immunodeficiency virus type 1: Genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. J. Virol. 70, 427-444.
31. Zolla-Pazner, S., O'Leary, J., Burda, S. et al. (1995). Sero typing of primary human immunodeficiency virus type 1 isolates from diverse geographic locations by flow cytometry. J. Virol. 69, 3807-3815.
32. Moore, J. P., Trkola, A., Korber, B. et al. (1995). A human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunodeficiency virus type 1 has broad reactivity within and outside clade B. J. Virol. 69, 122-130.
33. Trkola, A., Polamles, A. B., Yuan, H. et al. (1995). Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetameric CD4-IgG. J. Virol. 69, 6609-6617.
34. Trkola, A., Purtscher, M., Muster, T. et al. (1996). Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 70, 1100-1108.
35. Ditzel, H. J., Binley, J. M., Moore, J. P. et al. (1995). Neutralizing recombinant human antibodies to a conformational V2- and CD4-binding site-sensitive epitope of HIV-1 gp120 isolated by using an epitope-masking procedure. J. Immunol 154, 893-906.
36. Walker, M. C. and Fast, P. E. (1994). Clinical Trials of Candidate AIDS Vaccines. Current Sci. 8(1), S213-S236.
37. Dolin, R. (1996). Human studies in the development of human immunodeficiency virus vaccines. J. Infect. Dis. 172, 1175-1183.
38. Roberts, C. G. P., Meister, G. E., Jesdale, B. M., Lieberman, J., Berzofsky, J. A. and De Groot, A. S. (1996). Identification of HIV peptide epitopes by a novel algorithm. AIDS Res. Hum. Retrovir. 12, 593-610.
39. Meister, G. E., Roberts, C. G. P., Berzofsky, J. A. and De Groot, A. S. (1995). Two novel T cell epitope prediction algorithms based on MHC-binding motifs; comparison of predicted and published epitopes from Mycobacterium tuberculosis and HIV protein sequences. Vaccine 13, 581-591.
40. Oldstone, M. B. A., Lenwicki, H., Borrow, P., Hudrisier, D. and Gairin, J. E. (1995). Discrimination selection among viral peptides with the appropriate anchor residues: Implications for the size of the cytotoxic T-lymphocyte repertoire and control of viral infection. J. Virol. 69, 7423-7429.
41. Emini, E. A., Schleif, W. A., Nunberg, J. H. et al. (1992). Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. J. Virol. 355, 728-730.
42. Warren, J. T. and Dolatshahi, M. (1992). Worldwide survey of AIDS vaccine challenge studies in non-human primates: Vaccines associated with active and passive immune protection from live virus challenge. J. Med. Primatol. 21, 139-186.
43. Prince, A. M., Reesink, H., Pascual, D. et al. Prevention of HIV infection by passive immunization with HIV immunoglobulin. Eng. AIDS Res. Hum. Retrovir. 7, 971-973.
44. Girard, M., Barre-Sinnoussi, F., Paoletti, E. et al. (1996). Homologous and heterologous protection from HIV-1 infection in chimpanzees. In, Retroviruses of Human AIDS and Related Animal Diseases,ed. by M. Girard and B. Dodet, Foundation Marcel Merieux, Lyon, in press.
45. Berman, P. W., Murthy, K. K., Wrin, T. et al. (1996). Protection of MN-rgp120-immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficiency virus type 1. J. Infect. Dis. 173; 52-59.
46. el-Amad, Z., Murthy, K. K., Higgins, K. et al. (1995). Resistance of chimpanzees immunized with recombinant gp120SF2. AIDS 9, 1313-1322.
47. Berman, P. W., Gregory, T. J., Riddle, L. et al. (1990). Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. J. Virol. 345, 622-625.
48. Zhang, Y. J., Ohman, P., Putkonen, P. et al. (1993). Autologous neutralizing antibodies to SIVsm in cynomolgus monkeys correlate to prognosis. Virology 197, 609-615.
49. Sutjipto, S., Pedersen, N. C., Miller, C. J. (1990). Inactivated simian immunodeficiency virus vaccine failed to protect rhesus macaques from intravenous or genital mucosal infection but delayed disease in intravenously exposed animals. J. Virol. 64, 2290-2297.
50. Niedrig, M., Gregersen, J. P., Fultz, P. N., Mehdi, S. and Hilfenhaus, J. (1993). Immune response of chimpanzees after immunization with the inactivated whole immunodeficiency virus (HIV-1), three different adjuvants and challenge. Eng. Vaccine 11, 67-74.
51. Giavedoni, L. D., Flanelles, V., Haigwood, N. L. et al. (1993). Immune response of rhesus macaques to recombinant simian immunodeficiency virus gp130 does not protect from challenge infection. J. Virol. 67, 577-583.
52. Daniel, M. D., Mazzara, G. P., Simon, M. A. et al. (1994). High titer immune responses elicited by recombinant vaccinia virus priming and particle boosting are ineffective in preventing virulent SIV infection. AIDS Res. Hum. Retrovir. 10, 839-851.
53. Wyand, M. S., Manson, K. H., Garcia-Moll, M. and Desrosiers, R. C. (1996). Vaccine protection by a triple deletion mutant of simian immunodeficiency virus. J. Virol 70, 3724-3733.
54. Heeney, J., Holterman, L. ten Haaft, P. et al. (1994). Vaccine protection and reduced virus load from heterologous macaque-propagated SIV challenge. AIDS Res. Hum. Retrovir. 10, S117-S121.
55. Dittmer, U., Nisslein, T., Bodemer, W., Petry, H., Sauermann, U. and Hunsmann, G. (1995). Cellular immune response of rhesus monkeys infected with a partially attenuated nef deletion mutant of the simian immunodeficiency virus. Virology 212, 392-397.
56. Heeney, J. L., van Els, C., de Vries, P. et al. (1994). Major histocompatibility complex class I-associated vaccine protection from simian immunodeficiency virus-infected peripheral blood cells. Eng. J. Exp. Med. 180, 769-774.
57. Vogel, T., Beer, B., zur Megede, J. et al. (1996). Induction of anti-SIVmac cellular and humoral immune responses in rhesus macaques by peptide immunogens: reduction of virus load following challenge. In, Conference on Advances in AIDS Vaccine Development, Bethesda MD, February 11-15, 1996 Abstract, Natl. Inst. Allergy Infect. Dis., Bethesda, MD.
58. Shen, L., Chen, Z. W., Miller, M. D. et al. (1991). Recombinant virus vaccine-induced SIV-specific CD8+ cytotoxic T lymphocytes. Science 252, 440-443.
59. Yasutomi, Y., Koenig, S., Haun, S. S. et al. (1993). Immunization with recombinant BCG-SIV elicits SIV-specific cytotoxic T lymphocytes in rhesus monkeys. J. Immunol. 150, 3101-3107.
60. Yasutomi, Y., Palker, T. J., Gardner, M. B., Haynes, B. F. and Letvin, N. L. (1993). Synthetic peptide in mineral oil adjuvant elicits simian immunodeficiency virus-specific CD8+ cytotoxic T lymphocytes in rhesus monkeys. J. Immunol. 151, 5096-5105
61. Miller, M. D., Gould-Fogerite, S., Shen, L. et al. (1992). Vaccination of rhesus monkeys with synthetic peptide in a fusogenic proteoliposome elicits simian immunodeficiency virus-specific CD8+ cytotoxic T lymphocytes. J. Exp. Med. 176, 1739-1744.
62. Rinaldo, C., Huang, X-L., Fan, A. A.-M. et al. (1995). High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors. J. Virol. 69, 5838-5842.
63. Montefiori, D. C., Panteleo, G., Fink, L. M. et al. (1995). Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors. J. Infect. Dis. 173, 60-67.
64. Harrer, T., Harrer, E., Kalams, S. A. et al. (1996). Strong cytotoxic T cell and weak antibody responses in a subset of persons with stable non-progressing HIV-1 infection. AIDS Res. Hum. Retrovir. 12, in press.
65. De Maria, A., Cirillo, C. and Moretta, L. (1994). Occurrence of human immunodeficiency virus type a (HIV-1)-specific cytolytic T cell activity in apparently uninfected children born to HIV-1-infected mothers. J. Infect. Dis. 170, 1296-1299.
66. Pauza, D., Trivedi, P. and Johnson, E. (1994). Acquired resistance to mucosal SIV infection after low dose intrarectal inoculation: the roles of virus selection and CDS-mediated T cell immunity. In, Retroviruses of Human A.I.D.S. and Related Animal Diseases ed. by M. Girard and L. Valette, pp. 151-156. Lyon: Pasteur Merieux Serums & Vaccins.
67. Hasenkrug, K. J., Brooks, D. M. A.-J. and Chesebro, B. (1996). Differing T-cell requirements for recombinant retrovirus vaccines. J. Virol. 70, 368-372.
68. Cocchi, F., DeVico, A. L., Garzino-Demo, A., Arya, S. K., Gallo, R. C. and Lusso, P. (1995). Identification of RANTES, MIP-1 (and MIP-1 (as the major HIV-suppressive factors produced by CD8+ T cells. Science 270, 1811-1815.
69. Baier, M., Werner, A., Bannert, N. A., Karin and Kurth, R. (1995). HIV suppression by interleukin-16. J. Virol. 378, 563.
70. Musey, L., Eckert, L., Hu, Y., Cristensen, M., Akridge, R. and McElrath, J. (1996). HIV-specific mucosal immunity. In, Conference on Advances in AIDS Vaccine Development, Bethesda, MD February 11-15, 1996 Abstract, NIAID, Bethesda MD.
71. Poss, M., Martin, H. L., Kreiss, J. K. et al. (1995). Diversity in virus populations from genetal secretions and peripheral blood from women recently infected with human immunodeficiency virus type L. J. Virol. 69, 8118-8122.
72. Essex, M. (1996). Differential growth of HIV-1 subtypes in Langerhans' cells: implications for vaccine development. In, Retroviruses of Human AIDS and Related Animal Diseases,ed. by M. Girard and B. Dodet, Foundation Marcel Merieux, Lyon, in press.
73. Soto-Ramirez, L. E., Renjifo, B., McLane, M. F. et al. (1996), HIV-Langerhan's cell tropism associated with heterosexual transmission. Science 271, 1291-1293.
74. SF-2 in healthy volunteers. Annals Intern. Med., in press.
75. Dolin, R., Graham, B. S., Greenberg, S. B. et al. (1991). NIAID AIDS Vaccine Clinical Trials Network. The safety and immunogenicity of an HIV-1 rgp 160 candidate vaccine in humans. Ann. Intern. Med. 114(2) 119-127.
76. Belshe, R., Clements, M. L., Dolin, R. et al. (1993). NIAID AIDS Vaccine Clinical Trials Network. Safety and immunogenicity of a fully glycosylated rgp 160 HIV-1 vaccine in low risk volunteers. J. Infect. Dis. 168, 1387-1395.
77. Gorse, G. J., Schwartz, D. H., Graham, B. S. et al. (1994). HIV-1 recombinant gp 160 vaccine given in accelerated dose schedules. Clin. Exp. Immunol. 98, 178-184.
78. Salmon-Ceron, D., Excler, J-L, Sicard, D. et al. (1995). Safety and immunogenicity of a recombinant HIV type 1 glycoprotein 160 boosted by a V3 synthetic peptide in HIV-negative volunteers. AIDS Res. Human Retrovir. 11, 1479-1486.
79. Belshe, R. B., Graham, B. S., Keefer, M. C. et al. (1994). Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. JAMA 272, 475-480.
80. Walker, M. C. and Fast, P. E. (1994). Clinical trials of candidate AIDS vaccines. AIDS 8, S213-S236.
81. Kahn, J., Chernoff, D., Sinangil, F., Baenziger, J., Murcar, N. and Steimer, K. (1993). Phase 1 study of an HIV-1 gp 120 vaccine combined with MF59 and with dose escalation of MTP-PE, in sero-negative adults. Int. Conf. AIDS 9, 70 Abstract.
82. Wintsch, J., Chaignat, C. L., Braun, D. G. et al. (1991). Safety and immunogenicity of a genetically engineered human immunodeficiency virus vaccine. J. Infect. Dis. 163, 219-225.
83. Berman, P. W., Matthews, T. J., Riddle, L. et al. (1992). Neutralization of multiple laboratory and clinical isolates of human immunodeficiency virus type 1 (HIV-1) by antisera raised against gp120 from the MN isolate of HIV-1. Eng. J. Virol. 66, 4464-4469.
84. Vancott, T. C., Bethke, F. R., Burke, D. S., Redfield, R. R. and Birx, D. L. (1995). Lack of induction of antibodies specific for conserved discontinuous epitopes of HIV-1 envelope glycoprotein by candidate AIDS vaccines. J. Immunol. 155, 4100-4110.
85. Hanson, C. V. (1994). Measuring vaccine-induced HIV neutralization: report of a workshop. Eng. AIDS Res. Hum. Retrovir. 10, 645-648.
86. Mascola, J., Weislow, O., Snyder, S. et al. (1994). Neutralizing antibody activity in sera from human immunodeficiency virus type-1 vaccine recipients from the AIDS vaccine clinical trials network. AIDS Res. Hum. Retrovir. 10, S55.
87. Zolla-Pazner, S. and Sharpe, S. (1995). A resting cell assay for improved detection of antibody mediated neutralization of HIV type 1 primary isolates. AIDS Res. Hum. Retrovir. 11, 1449-1458.
88. Zolla-Pazner, S., Berman, P., Xu, S. and Gregory, T. (1996). Detection of primary isolate-neutralizating antibodies in the sera of humans immunized with rgp120(MN) vaccine. Conference on Advance in AIDS Vaccine Development, Bethesda MD, February 11-15 Abstract, NIAID, Bethesda, MD.
89. Bruck, C., Thiriart, C., Delers, A. et al. (1993). Comparison of vaccine protection in chimpanzees immunized with two different forms of recombinant HIV-1 envelope glycoprotein. AIDS Res. Hum. Retrovir. 9 (Suppl. 1), S110 Abstract.
90. Girard, M., Meignier, B., Barre-Sinoussi, F. et al. (1995). Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1. J. Virol. 69, 6239-6248.
91. Giavedoni, J., Planelles, V., Haigwood, N. L. et al. (1993). Immune response of rhesus macaques to recombinant simian immunodeficiency virus gp130 does not protect from challenge infection. J. virol. 67, 577-583.
92. Barnett, S. W., Klinger, J. M., Legg, H., Luciw, P. A., Murphey-Corb, M. and Steimer, K. S. (1996). Recombinant gp120SF2/MF59 subunit immunization does not protect rhesus macaques from intravenous challenge with heterologous SHIV33. In, Conference on Advances in AIDS Vaccine Development, Bethesda MD, February 11-15, 1996 Abstract, NIAID, Bethesda, MD.
93. Weiss, C. D., Levy, J. A. and White, J. M. (1990). Oligomeric organization of gp120 on infectious human immunodeficiency virus type 1 particles. J. Virol. 64, 5674-5677.
94. Earl, P. L., Doms, R. W. and Moss, B. (1990). Oligomeric structure of the human immunodeficiency type 1 envelope glycoprotin. Proc. Natl Acad. Sci. USA 87, 648-652.
95. Poumbourios, P., El Ahmar, W., McPhee, D. A. and Kemp, B. E. (1995). Determinants of human immunodeficiency virus type 1 envelope glycoprotein oligomeric structure. J. Virol. 69, 1209-1218.
96. Richardson, T. M., Stryjewski, B. L., Broder, C. C. et al. (1996). Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein. J. Virol. 70, 753-762.
97. Broder, C. C., Early, P., Long, D., Abedon, S. T., Moss, B. and Doms, R. W. (1994). Antigenic implications of human immunodeficiency virus type-1 envelope quaternary structure, oligomer-specific and -sensitive monoclonal antibodies. Proc. Natl Acad. Sci. USA 91, 11699-11703.
98. Mascola, J. R., Vancott, T. C., Louder, M. et al. (1996). Neutralizing antibody against primary HIV-1 isolates elicited by immunization with oligomeric, but not monomeric, env glycoprotein. Conference on Advances in Vaccine Research, Bethesda MD, February 11-15, 1996 Abstract, NIAID, Bethesda, MD.
99. Luke, W., Petry, H., Dittmer, U. et al. (1996). Immunization with gp130 oligomers but not gp130 monomers partially protects rhesus macaqus against the productive infection with SIVmac32H and disease development. In, Conference on Advances in AIDS Vaccine Development, Bethesda MD, February 11-15 Abstract, NIAID, Bethesda, MD.
100. Hart, M. K., Weinhold, K. J., Scearce, R. M. et al. (1991). Priming of anti-human immunodeficiency virus (HIV) CD8+ cytotoxic T cells in vivo by carrier-free HIV synthetic peptides. Proc. Natl Acad. Sci. USA 88, 9448-9452.
101. Hart, M. K., Palker, T. J., Matthews, T. J. et al. (1990). Synthetic peptides containing T and B cell epitopes from human immunodeficiency virus envelope gp120 induce anti-HIV proliferative responses and high titers of neutralizing antibodies in rhesus monkeys. J. Immunol. 145, 2677-2685.
102. Weiser, B., Burger, H., Steimer, K. et al. (1987). Antibody to human immunodeficiency virus correlates with decreased T helper lymphocytes in asymptomatic individuals. J. Med. Virol. 22, 237-244.
103. Palker, T. J., Matthews, T. J., Langlois, A. et al. (1989). Polyvalent human immunodeficiency virus synthetic immunogen comprised of envelope gp120 T helper cell sites and B cell neutralization epitopes. J. Immunol. 142, 3612-3619.
104. Berzofsky, J. A., Bensussan, A., Cease, K. B. et al. (1988). Antigenic peptides recognized by T lymphocytes from AIDS viral envelope-immune humans. J. Virol. 334, 706-708.
105. Ahlers, J. D., Pendleton, C. D., Dunlop, N., Minassian, A., Nara, P. L. and Berzofsky, J. A. (1993). Construction of an HIV-1 peptide vaccine containing a multideterminant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody responses in mice of multiple MHC haplotypes after two immunizations. J. Immunol. 150, 5647-5665.
106. Hulskette, E. G., Geretti, A.-M., Siebelink, K. H. J. et al. (1995). Vaccine-induced virus-neutralizing antibodies and cytotoxic T cells do not protect macaques from experimental infection with simian immunodeficiency virus SIVmac32H (J5). J. Virol. 69, 6289-6296.
107. Gorse, G. J., Keefer, M. C., Belshe, R. B. et al. (1996). A dose-ranging study of a prototype synthetic HIV-1MN V3 branched peptide vaccine. J. Infect. Dis. 173, 330-339.
108. Shafferman, A., Lewis, M. G., McCutchan, F. E. et al. (1993). Prevention of transmission of simian immunodeficiency virus from vaccinated macaques that developed transient virus infection following challenge. Vaccine 11, 848-852.
109. Staats, H. F. and Palker, T. J. (1996). Induction of persistent serum and vaginal anti-HIV antibody responses by intranasal immunization with HIV peptides and cholera toxin. In, Conference on Advances in AIDS Vaccine Research, Bethesda MD, February 11-15, 1996 Abstract, NIAID, Bethesda, MD.
110. Cooney, E. L., Collier, A. C., Greenberg, P. D. et al. (1991). Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein [see comments]. Lancet 337, 567-572.
111. Graham, B. S., Belshe, R. B., Clements, M. L. et al. (1992). Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. The AIDS Vaccine Clinical Trials Network. J. Infect. Dis. 166, 244-252.
112. el-Daher, N., Keefer, M. C., Reichman, R. C., Dolin, R. and Roberts, N. J., Jr. (1993). Persisting human immunodeficiency virus type 1 gp160-specific human T lymphocyte responses including CD8 + cytotoxic activity after receipt of envelope vaccines. J. Infect. Dis. 168, 306-313.
113. Graham, B. S., Matthews, T. J., Belshe, R. B. et al. (1993). Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network. J. Infect. Dis. 167, 533-537.
114. Montefiori, D. C., Graham, B. S., Kliks, S. and Wright, P. F. (1992). Serum antibodies to HIV-1 in recombinant vaccinia virus recipients boosted with purified recombinant gp160. NIAID AIDS Vaccine Clinical Trials Network. J. Clin. Immunol. 12, 429-439.
115. Cooney, E. L., McElrath, M. J., Corey, L. et al. (1993). Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein. Proc. Natl Acad. Sci. USA 90, 1882-1886.
116. Perales, M., Schwartz, D. H., Fabry, J. A. and Lieberman, J. (1995). A Vaccinia-gp160-based Vaccine But Not a gp160 Protein Vaccine Elicits Anti-gp160 Cyctotoxic T Lymphocytes in Some HIV-1 Seronegative Vaccinees. J. AIDS Hum. Retrovirol. 10, 27-35.
117. McElrath, M. J., Hoffman, M. Kluckling, S., Corey, L. and Greenberg, P. D. (1994). HIV-infected macrophages as efficient stimulator cells for detection of cytotoxic T cell responses to HIV in seronegative and seropositive vaccine recipients. AIDS Res. Hum. Retrovir. 10, 541-549.
118. Mosier, D. E., Gulizia, R. J., Maclsaac, P. D., Corey, L. and Greenberg, P. D. (1993). Resistance to human immunodeficiency virus 1 infection of SCID mice reconstituted with peripheral blood leukocytes from donors vaccinated with vaccinia gp160 and recombinant gp160. Proc. Natl Acad. Sci. USA 90, 2443-2447.
119. Hu, S. L., Abrams, K., Barber, G. N. et al. (1992). Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160. Science 255, 456-459.
120. Panicali, D. L., Mazzara, G., Sullivan, J. L. et al. (1992). Use of lentivirus-like particles alone and in combination with live vaccinia-virus-based vaccines. AIDS Res. Hum. Retrovir. 8, 1449.
121. Desrosiers, R. C. (1996). Non-human primate models for AIDS vaccines. AIDS 9, S137-S141.
122. Hu, S. L., Polacino, P., Klaniecki, J. et al. (1996). Recombinant vaccine protection against intravenous and intrarectal challenge with uncloned SIVmne and its implications for HIV vaccine development. In, Conference on Advances in AIDS Vaccine Development, Bethesda MD, February 11-15, 1996 Abstract, NIAID, Bethesda, MD.
123. Siebelink, K. H. J., Tijhaar, E., Huisman, R. C. et al. (1995). Enhancement of Feline Immunodeficiency Virus Infection after Immunization with Envelope Glycoprotein Subunit Vaccines. J. Virol. 69, 3704-3711.
124. Cadoz, M., Strady, A., Meignier, B. et al. (1992). Immunisation with canarypox virus expressing rabies glycoprotein. Lancet 339, 1429-1432.
125. Taylor, J., Weinberg, R., Tartaglia, J. et al. (1992). Nonreplicating viral vectors as potential vaccines: recombinant canarypox virus expressing measles virus fusion (F) and hemagglutinin (HA) glycoproteins. Virology 187, 321-328.
126. Salmon-Ceron, D., Excler, J.-L., Sicard, D. et al. A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). AIDS Res. Hum. Retrovir. 11, 373-381.
127. Clements, M.L., Eagan, M., Schwartz, D. et al. (1994). Humoral and cell-mediated immune responses of HIV-1 seronegative volunteers following prime-boost with canarypox (ALVAC)-MN gp 160 alone or with SF2 gp 120-MF59 subunit vaccine. National Coop Vaccine Development Groups for AIDS Abstract.
128. 1mn env gene. J. Infect. Dis. 171, 1623-1627.
129. Excler, J. L., Salmon, D., Sicard, D. et al. (1995). Safety and immunogenicity of a live recombinant canarypox virus vaccine expressing gp120/gag/ protease boosted by a p24E-V3 peptide. AIDS Res. Hum. Retrovir. 11, 293.
130. Salmon, D., Finkielstzjen, L., Excler, J. L. et al. (1996). Exploration of mucosal immunity in HIV-1 in infection and its application to vaccine trials. In, Conference on Advances in AIDS Vaccine Development, Bethesda MD, February 11-15, 1996 Abstract, NIAID, Bethesda, MD.
131. Franchini, G., Robert-Guroff, M., Tartaglia, J. et al. (1995). Highly Attenuated HIV Type 2 Recombinant Poxviruses, but Not HIV-2 Recombinant Salmonella Vaccines, Induce Long-Lasting Protection in Rhesus Macaques. AIDS Res. Hum. Retrovir. 11, 909-920.
132. Tartaglia, J., Jarrett, O., Neil, J. C., Desmettre, P. and Paoletti, E. (1993). Protection of cats against feline leukemia virus by vaccination with a canarypox virus recombinant, ALVAC-FL. J. Virol. 67, 2370-2375.
133. Natuk, R. J., Lubeck, M. D., Chanda, P. K. et al. (1993). Immunogenicity of recombinant human adenovirus-human immunodeficiency virus vaccines in chimpanzees. AIDS Res. Hum. Retrovir. 9, 395-404.
134. MN ENV recombinants and a SF2 GP120 boost protect chimpanzees from a SF2 challenge. AIDS Res. Hum. Retrovir. 11, 285.
135. Zolla-Pazner, S., Lubeck, M., Robert-Guroff, M. et al. (1996). Presence of neutralizing antibodies for primary isolates in immunized chimps correlates with protection in vivo. In, 3rd Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 28-February 1 Abstract, Infectious Disease Society of America, Alexandria, VA.
136. Dedieu, J. F., Ronco, J., van der Werf, S., Hogle, J. M., Henin, Y. and Girard, M. (1992). Poliovirus chimeras expressing sequences from the principal neutralization domain of human immunodeficiency virus type 1. J. Virol. 66, 3161-3167.
137. Burke, K. L., Almond, J. W. and Evans, D. J. (1991). Antigen chimeras of poliovirus. Prog. Med. Virol. 38, 56-68.
138. Evans, D. J., McKeating, J., Meredith, J. M. et al. (1989). An engineered poliovirus chimera elicits broadly reactive HIV-1 neutralizing antibodies. Nature 339, 385-388.
139. Altmeyer, R., Escriou, N., Girard, M., Traincard, F., Arondel, J. and van der Werf, S. (1993). Recombinant Mengovirus as a novel approach to live vaccine development against HIV. Int. Conf. AIDS 9, 37 Abstract.
140. Muster, T., Ferko, B., Klima, A. et al. (1995). Mucosal model of immunization against human immunodeficiency virus type 1 with a chimeric influenza virus. J. Immunol. 69, 6678-6686.
141. Smith, A. D., Resnick, D. A., Zhang, A., Geisler, S. C., Arnold, E. and Arnold, G. F. (1994). Use of random systematic mutagenesis to generate viable human rhinovirus 14 chimeras displaying human immunodeficiency virus type 1 V3 loop sequences. Eng. J. Virol. 68, 575-579.
142. Resnick, D. A., Smith, A. D., Geisler, S. C., Zhang, A., Arnold, E. and Arnold, G. (1995). Chimeras from a Human Rhinovirus 14-Human Immunodeficiency Type 1 (HIV-1) V3 Loop Seroprevalence Library Induce Neutralizing Responses against HIV-1. J. Virol. 69, 2406-2411.
143. Fouts, T. R., Lewis, G. K. and Hone, D. M. (1993). Construction and characterization of a Salmonella-based HIV-1 vector vaccine. In, Vaccines 93: Modern Approaches to New Vaccines including Prevention of AIDS ed. by H. Ginsberg, F. Brown, R. M. Chanock and R. A. Lerner, pp. 95-99. Cold Spring Harbor Laboratory, Cold Spring Harbor, New York.
144. Berggren, R. E., Wunderlich, A., Zeigler, E. et al. (1995). HIV gp120-specific cell-mediated immune responses in mice after oral immunization with recombinant salmonella. J. AIDS Hum. Retrovirol 10, 489-495.
145. Aggarwal, A., Sadoff, J., Markham, P., Gallo, R. and Franchini, G. (1991). Induction of cytotoxic T lymphocytes against HIV-2 in mice immunized with recombinant salmonella typhimurium. Int. Conf. AIDS 7, 101 Abstract.
146. Fuerst, T. R., Stover, C. K. and de la Cruz, V. F. (1991). Development of BCG as a live recombinant vector system: potential use as an HIV vaccine. Biotechnol. Ther. 2, 159-178.
147. Aldovini, A. and Young, R. A. (1990). Development of a BCG recombinant vehicle for candidate AIDS vaccines. Int. Rev. Immunol. 7, 79-83.
148. Aldovini, A. and Young, R. A. (1991). Humoral and cell-mediated immune responses to live recombinant BCG-HIV vaccines. Nature 351, 479-482.
149. Aldovini, A. and Young, R. A. (1991). Humoral and cell-mediated immune responses to live recombinant BCG-HIV vaccines. J. Virol. 351, 479-482.
150. Armbruster, C., Junker, W., Vetter, N. and Jaksch, G. (1990). Disseminated bacille Calmette-Guerin infection in an AIDS patient 30 years after BCG vaccination [letter]. J. Infect. Dis. 162, 1216.
151. Honda, M., Matsuo, K., Nakasone, T. et al. (1995). Protective immune response induced by secretion of a chimeric soluble protein from a recombinant Mycobacterium bovis bacillus Calmette-Gerin vector candidate vaccine for human immunodeficiency virus type 1 in small animals. Proc. Natl Acad. Sci. (USA) 92, 10693-10697.
152. Almond, N., Kent, K., Cranage, M., Rud, E., Clarke, B. and Stott, E. J. (1995). Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cells. Lancet 69, 3117-3124.
153. Marthas, M., Miller, C. J., Sutjipto, S. et al. (1992). Efficacy of live-attenuated and whole-inactivated simian immunodeficiency virus vaccines against vaginal challenge with virulent SIV Efficacy of live-attenuated and whole-inactivated simian immunodeficiency virus vaccines against vaginal challenge with virulent SIV. J. Med. Primatol. 21, 99-107.
154. Bogers, W. M. J. M. Niphuis, H., Haaft, P.T., Laman, J. D., Koornstra, W. and Heeney, J. L. (1995). Protection from HIV-1 envelope-bearing chimeric simian immunodeficiency virus (SHIV) in rhesus macaques infected with attenuated SIV: consequences of challenge. AIDS 9, F13-F18.
155. Denesvre, C., Le Grand, R., Boissin-Cans, F. et al. (1995). Highly attenuated SIVmac251 challenge. AIDS Res. Hum. Retrovir. 11, 1397-1406.
156. Baba, T. W., Jeong, Y. S., Penninck, D., Bronson, R., Greene, M. F. and Ruprecht, R. (1995). Pathogenicity of live attenuated SIV after mucosal infection of neonatal macaques. Science 267, 1820-1825.
157. Yilma, T., Jones, L., Luciw, P., Ahmad, S. and Giavedoni, L. D. (1996). Expression of interferongamma by simian immunodeficiency virus increases attenuation and vaccine efficacy for rhesus macaques. In, Conference on Advances in AIDS Vaccine Research, Bethesda MD, February 11-15, 1996 Abstract, NIAID, Bethesda, MD.
158. Marthas, M. L. (1996). Pathogenesis of SIV variants in neonatal rhesus macaques. In, Retroviruses of Human AIDS and Related Animal Diseases,ed. by M. Girard and B. Dodet, Foundation Marcel Merieux, Lyon, in press.
159. Kirchhoff, F., Greenough, T. C., Brettler, D. B., Sullivan, J. L. and Desrosiers, R. C. (1995). Brief report: Absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. N Engl. J. Med. 332, 226-232.
160. Deacon, N. J., Tsykin, A., Solomon, A. et al. (1995). Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science, 270, 988-991.
161. Desrosiers, R. C. (1994). Controversies in Science. Yes, it is time to consider use of a live-attenuated virus vaccine against HIV-1. J. NIH Res. 6, 54-59.
162. Bolognesi, D. P. (1994). A live-virus AIDS vaccine? Not Yet, it is too early to consider use of a live-attenuated virus vaccine against HIV-1. J. NIH RES. 6, 55-62.
163. Sattentau, Q. J. (1995). Conservation of HIV-1 gp120 neutralizing epitopes after formulin activation. AIDS 9, 1383-1385.
164. Murphey-Corb, M., Martin, L. N., Davison-Fairbum, B. et al. (1989). A formalin-inactivated whole SIV vaccine confers protection in macaques. Science 246, 1293-1297.
165. Stott, E. J. (1991). Anti-cell antibody in macaques [letter]. J. Virol. 353, 393.
166. Langlois, A. J., Weinhold, K. J., Matthews, T. J., Greenberg, M. L. and Bolognesi, D. P. (1992). Detection of anti-human cell antibodies in sera from macaques immunized with whole inactivated virus. AIDS Res. Hum. Retrovir. 8, 1641-1652.
167. Stott, E. J. (1991). Anticell antibody in macaques. Nature 353, 393.
168. Putkonen, P., Nilsson, C., Hild, K. et al. (1993). Whole inactivated SIV vaccine grown on human cells fails to protect against homologous SIV grown on simian cells. J. Med. Primatol. 22, 100-103.
169. Hirsch, V. M., Goldstein, S., Hynes, N. A. et al. (1994). Prolonged clinical latency and survival of macaques given a whole inactivated simian immunodeficiency virus vaccine. Eng. J. Infect. Dis. 170, 51-59.
170. Yamamoto, J. K., Hohdatsu, T., Olmsted, R. A. et al. (1993). Experimental vaccine protection against homologous and heterologous strains of feline immunodeficiency virus. J. Virol. 67, 601-605.
171. Hosie, M. J., Osbome, R., Yamamoto, J. K., Neil, J. C. and Jarrett, O. (1995). Protection against homologous but not heterologous challenge induced by inactivated feline immunodeficiency virus vaccines. J. Virol. 96, 1253-1255.
172. Griffiths, J. C., Harris, S. J., Lay ton, G. T. et al. (1993). Hybrid human immunodeficiency virus Gag particles as an antigen carrier system: induction of cytotoxic T-cell and humoral responses by a Gag:V3 fusion. J. Virol. 67, 3191-3198.
173. Wagner, R., Fliessbach, H., Wanner, G. et al. (1992). Studies on processing, particle formation and immunogenicity of the HIV-1 gag gene product: a possible component of a HIV vaccine. Arch. Virol. 127, 117-137.
174. Layton, G. T., Harris, S. J., Gearing, A. J. et al. (1993). Induction of HIV-specific cytotoxic T lymphocytes in vivo with hybrid HIV-1 V3:Ty-virus-like particles. Engl J. Immimol. 151, 1097-1107.
175. gag based viruslike particles: A basis for novel HIV vaccines. Conference on Advances in AIDS Vaccine Research, Bethescia MD, February 11-15, 1996 Abstract.
176. Rovinski, B., Haynes, J. R., Cao, S. X. et al. (1992). Expression and characterization of genetically engineered human immunodeficiency virus-like particles containing modified envelope glycoproteins: implications for development of a cross-protective AIDS vaccine. J. Virol. 66, 4003-4012.
177. Haffar, O., Garrigues, J., Travis, B., Moran, P., Zarling, J. and Hu, S. L. (1990). Human immunodeficiency virus-like, nonreplicating, gag-env particles assemble in a recombinant vaccinia virus expression system. J. Virol. 64, 2653-2659.
178. Haynes, J. R., Cao, S. X., Rovinski, B. et al. (1991). Production of immunogenic HIV-1 viruslike particles in stably engineered monkey cell lines. AIDS Res. Hum Retrovir. 7, 17-27.
179. Vzorov, A. N., Bukrinsky, M. I., Grigoriev, V. B., Tentsov, Y. Y. and Bukrinskaya, A. G. (1991). High immunogenic human immunodeficiency viruslike particles are produced by recombinant vaccinia virus-infected cells. AIDS Res. Hum. Retrovir. 7, 29-36.
180. Yasutomi, Y., Robinson, H. L., Lu, S. et al. (1996). Simian immunodeficiency virus-specifc cytotoxic T-lymphocyte induction through DNA vaccination of rhesus monkeys. Virology 70, 678-681.
181. Wang, B., Ugen, K. E., Srikantan, V. et al. (1993). Gene inoculation generates immune responses against human immunodeficiency virus type 1. Proc. Natl Acad. Sci. USA 90, 4156-4160.
182. Weiner, D. B., Wang, B. et al. (1995). Induction of humoral and cellular immune responses to the human immunodeficiency type 1 virus in nonhuman primates by in vivo DNA inoculation. Virology 211, 261-267.
183. Haynes, J. R., Fuller, D. and Eisenbraun, M. (1993). In vivo delivery of HIV and SIV antigen-encoded vectors by particle bombardment as an alternative to live recombinant viruses for the induction of humoral and cellular immunity. AIDS Res. Hum. Retrovir. 9, 575.
184. Liu, M. A. and Vogel, F. R. (1994). Use of novel DNA vectors and immunologic adjuvants in HIV vaccine development. AIDS 8 (Suppl. 1), S195-S201.